2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

Abstract Number: 2599

Quality of Care for Medicare Recipients with Rheumatoid Arthritis: Vulnerable Populations More Likely to Receive Therapy with Glucocorticoids Alone
Abstract Number: 96

Quality of Care: Reference and Counter Reference From Family Physicians and Rheumatologists’ perspectives– A Pilot Study
Abstract Number: 1872

Quality of Reporting in Pharmacological Randomized Controlled Trials for Fibromyalgia
Abstract Number: 2689

Quality of Sleep, Physical Activity and Fatigue in Patients with Rheumatoid Arthritis. A Cross-Sectional Study
Abstract Number: 1619

Quantification of Bone Marrow Edema by Using Magnetic Resonance Imaging for the Assessment of Neck Pain Only Marginally Reflects Clinical Evaluation in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 2104

Quantitation in Patients with Rheumatoid Arthritis of Inflammation, Joint Damage and “Unexplained Symptoms” (e.g., Fibromyalgia) in Addition to Overall Status, According to 4 Physician Global Estimates Scored 0-10
Abstract Number: 26

Quantitative Analysis of Bone Damage Morphological Changes in the Citrullinated Collagen Induced Arthritis Mouse Model Using Micro CT
Abstract Number: 2584

Quantitative and Semi-Quantitative Bone Erosion Assessment On High-Resolution Peripheral Quantitative Computed Tomography in Rheumatoid Arthritis
Abstract Number: 128

Quantitative Assessment of Synovitis in Patients with Rheumatoid Arthritis Using Fluorescence Optical Imaging
Abstract Number: 1696

Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone

Jump to: View All • a b c d e f g h i j k l m n o p [q] r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].